share_log

Lender Requests to Convert Loan to MindBio Shares

Lender Requests to Convert Loan to MindBio Shares

貸款人要求將貸款轉換爲MindBio股票
Accesswire ·  04/16 06:40

VANCOUVER, BC / ACCESSWIRE / April 16, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio") is pleased to announce Riverfort Global Opportunities PCC Ltd has requested to convert CAD$100,000 of its loan to 2,000,000 MindBio shares ("Shares") at $0.05 per Share. All Shares will be subject to a hold period of four-months and one day from the date of issuance under applicable securities laws.

不列顛哥倫比亞省溫哥華/ACCESSWIRE/2024年4月16日/MindBio Therapeutics Corp.(CSE: MBIO)(法蘭克福:WF6)(“公司” 或 “MindBio”)欣然宣佈,Riverfort Global Opportunities PCC Ltd已要求以每股0.05美元的價格將其10萬加元的貸款轉換爲2,000,000股MindBio股票(“股票”)。根據適用的證券法,自發行之日起,所有股票的持有期爲四個月零一天。

Receive our latest updates here:

在此處接收我們的最新更新:

Follow MindBio on LinkedIn:

在領英上關注 MindBio:

Follow CEO Justin Hanka on LinkedIn:

在領英上關注首席執行官賈斯汀·漢卡:

For further information, please contact:

欲了解更多信息,請聯繫:

Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com

賈斯汀·漢卡,首席執行官
61 433140886
justin@mindbiotherapeutics.com

Media Inquiries

媒體查詢

Kristina Spionjak
pr@hlthcommunications.com

克里斯蒂娜·斯皮昂賈克
pr@hlthcommunications.com

About MindBio Therapeutics

關於 MindBio Therape

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials. MB22001 is MindBio's lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy partipicipants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

MindBio是一家領先的生物技術/生物製藥公司,專注於爲心理健康問題創造新的和新興的治療方法,並且正在進行世界上第一個帶回家的微劑量(MB22001)人體臨床試驗。MB22001 是 MindBio 的主要候選藥物,一種專有的可滴定形式的麥角酸二乙酰胺 (LSD),專爲帶回家的微劑量而設計。MindBio是迷幻藥物微劑量的領導者,正在通過臨床試驗推進其藥物和技術方案。MindBio已經開發了一個用於開發治療的多學科平台,並參與迷幻藥物開發和數字療法,已經完成了對80名健康參與者的1期臨床試驗,一項2a期臨床試驗剛剛完成了對重度抑鬱症患者的微劑量,目前正在進行一項2B期臨床試驗,對面臨生存困擾的晚期癌症患者進行微劑量。MindBio投資的研究爲開發經臨床驗證的新療法奠定了基礎,包括數字技術和干預措施,以治療抑鬱、焦慮和其他相關心理健康狀況等使人衰弱的健康狀況。

Cautionary Note Concerning Forward-Looking Statements:

關於前瞻性陳述的警示性說明:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

該新聞稿包含適用證券法所指的 “前瞻性陳述”。前瞻性陳述可以通過以下詞語來識別:“預期”、“打算”、“預算”、“相信”、“項目”、“估計”、“預期”、“預期”、“戰略”、“未來”、“可能”、“可能”、“會”、“應該”、“將” 以及對未來時期或負面時期的類似提法或類似的術語, 以及將來通常使用的術語和有條件的術語.前瞻性陳述基於截至提供之日的假設。但是,無法保證此類假設會反映這些項目或因素的實際結果。

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

此外,一些已知和未知的風險因素可能導致公司的實際業績和財務狀況與前瞻性陳述中指出的業績和財務狀況存在重大差異。因此,您不應依賴這些前瞻性陳述中的任何一項。可能導致實際業績和財務狀況與前瞻性陳述中所述業績和財務狀況存在重大差異的重要風險因素包括:加拿大和澳大利亞的總體經濟、市場和商業狀況;市場波動;本新聞稿中描述的任何交易或事件的時間表出現不可預見的延遲。本警示聲明完全限定了所有前瞻性信息。

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

除非法律要求,否則公司沒有義務修改或更新任何此類前瞻性陳述,也沒有義務公開宣佈對本文包含的任何前瞻性信息進行任何修訂的結果,以反映未來的業績、事件或發展。

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

SOURCE: MindBio Therapeutics

來源:MindBio Therapeutic


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論